Article

Women with IBD Have Lower Success Rates with Assisted Reproductive Treatments

Author(s):

Women suffering from ulcerative colitis (UC) and Crohn’s disease (CD) experience lower success rates per embryo transfer when they undergo assisted reproductive technology (ART) treatments than women who do not have inflammatory bowel disease (IBD).

Women suffering from ulcerative colitis (UC) and Crohn’s disease (CD) experience lower success rates per embryo transfer when they undergo assisted reproductive technology (ART) treatments than women who do not have inflammatory bowel disease (IBD).

The study published in Gut assessed data from Danish health registries of women who had an embryo transfer between January 1994 and January 2013.

Sonia Friedman, MD, Odense University Hospital in Denmark, and colleagues evaluated for differences in the chance of live births and unfavorable birth outcomes in women with UC and CD compared with those who did not have IBD.

Findings suggested that compared with women without IBD, the probability of having a live birth for each embryo transfer in women who received ART treatment was significantly reduced in women with UC.

Additionally, the risk for preterm birth was notably increased for women with UC.

The authors concluded, “Our results suggest that women with UC and CD receiving ART treatments cannot expect the same success for each embryo transfer as other infertile women. Women with CD may seek to initiate assisted reproductive technology treatment before needing CD surgery. Increased prenatal observation in UC pregnancies after ART should be considered.”

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD
Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD
Lauren Collen, MD: Some Fragrances May be More Prevalent in Exposomes of Children with Crohn’s Disease
© 2024 MJH Life Sciences

All rights reserved.